Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study
| Autor: | Leonardo Piscitelli, Francesco Messina, Stefano Piaserico, Giulia Odorici, Matteo Megna, Luiz Fernando Carvalho Leite, Francesca Prignano, Curdin Conrad, Piergiorgio Malagoli, Andrea Chiricozzi, Francesca Gaiani, Salvatore Panduri, Paolo Dapavo, Simone Ribero, Andrea Conti, Alessia Nidegger, Paulo Ferreira, Tiago Torres, Anna Balato, Pedro Mendes-Bastos, Joana Valerio |
|---|---|
| Přispěvatelé: | Chiricozzi, Andrea, Balato, Anna, Conrad, Curdin, Conti, Andrea, Dapavo, Paolo, Ferreira, Paulo, Gaiani, Francesca Maria, Leite, Luiz, Malagoli, Piergiorgio, Mendes-Bastos, Pedro, Megna, Matteo, Messina, Francesco, Nidegger, Alessia, Odorici, Giulia, Panduri, Salvatore, Piaserico, Stefano, Piscitelli, Leonardo, Prignano, Francesca, Ribero, Simone, Valerio, Joana, Torres, T |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Moderate to severe medicine.medical_specialty effectiveness Dermatology Antibodies Monoclonal Humanized Severity of Illness Index Antibodies Drug Administration Schedule 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Psoriasis Monoclonal medicine Humans DLQI Humanized Secukinumab Aged Retrospective Studies 030203 arthritis & rheumatology Plaque psoriasis Biological Products business.industry Retrospective cohort study psoriasis Middle Aged medicine.disease humanities Europe absolute PASI IL-17 Treatment Outcome Female Interleukin 17 Settore MED/35 - MALATTIE CUTANEE E VENEREE business effectivene |
| Popis: | Objective This European, multicentric, retrospective study aimed to collect data on secukinumab effectiveness in a real-world setting. Research design and methods: All psoriatic patients starting secukinumab between January 2016 and February 2017 in 11 European centers were followed until February 2018 and retrospectively evaluated. Main outcome measures: Secukinumab effectiveness was assessed by relative improvement from baseline of the Psoriasis Area Severity Index (PASI) and absolute PASI score modifications throughout 52 weeks of therapy. Additionally measures assessing effectiveness were used, including improvements of body surface area (BSA) and Dermatology Life Quality Index (DLQI). Results Out the 330 patients with potentially 52-week treatment duration, naïve to biologics patients showed greater probability to achieved PASI score of ≤1, ≤2, ≤3, and ≤5 at week 12, compared to bio-experienced patients (45.86% vs. 27.17%, 62.42% vs. 42.42%, 73.89% vs. 57.80%, and 84.08% vs. 74.57%, respectively). The greater effectiveness of secukinumab treatment in bio-naïve patients was confirmed at week 24 and 52. Conclusions In this real-world experience, secukinumab was proven effective in treating psoriasis patients throughout a 52-weeks observation period, with higher response in bio-naïve patients. This study may contribute to defining the clinical profile of secukinumab best-responders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|